Paragon Therapeutics’ Oruka Merges With ARCA to Advance Novel Treatments for PsO, PsA
Paragon Therapeutics’ Oruka is merging with ARCA biopharma to advance novel treatments for chronic skin diseases. In support of the all-stock transaction, Oruka has raised $275 million from a syndicate of healthcare investors. Oruka is Paragon’s third offshoot, following Spyre Therapeutics and Apogee Therapeutics. The combined company, which plans to operate under the name Oruka Therapeutics, […]